<DOC>
	<DOCNO>NCT02078973</DOCNO>
	<brief_summary>Tolvaptan selective vasopressin receptor antagonist ( V2R ) increase free water sodium excretion . Inhibition V2R increase vasopressin concentration plasma , stimulate V1-receptors vascular bed may change central brachial hemodynamics plasma concentration vasoactive hormone . The purpose study measure effect tolvaptan renal handling water sodium , systemic hemodynamics vasoactive hormone baseline nitric oxide ( NO ) -inhibition L-NG-monomethyl-arginine ( L-NMMA ) .</brief_summary>
	<brief_title>Effect Aquaretic Tolvaptan Nitric Oxide System . A Dose-response Study ( DOVA )</brief_title>
	<detailed_description />
	<mesh_term>Tolvaptan</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Men woman , age 1840 year Body Mass Index ( BMI ) 18,530 kg/m2 Anamnestic clinical sign heart , lung , lever , kidney brain disease Neoplastic disease Drug abuse Alcohol abuse Medical treatment except peroral anticontraceptive Pregnancy Smoking Abnormal blood urine sample Abnormal ECG Blood donation within month examination Arterial hypertension ( &gt; 140 mmHg systolic and/or 90 mmHg diastolic )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tolvaptan</keyword>
	<keyword>L-NMMA</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Nephrology</keyword>
</DOC>